相关实验视频

Updated: Jul 14, 2026

A Fluorogenic Peptide Cleavage Assay to Screen for Proteolytic Activity: Applications for coronavirus spike protein activation

A Fluorogenic Peptide Cleavage Assay to Screen for Proteolytic Activity: Applications for coronavirus spike protein activation

Published on: January 9, 2019

针对SARS-CoV-2主要蛋白酶:使用先进的虚拟查,分子动力学和体外验证的综合方法

Smbat Gevorgyan^1,2, Hamlet Khachatryan^3,4, Anastasiya Shavina^3,4

¹Laboratory of Antiviral Drug Discovery. Institute of Molecular Biology of National Academy of Sciences, 0014, Yerevan, Armenia. smbatg@denovosciences.ai.

Virology journal

|December 20, 2024

概括

研究人员确定了针对SARS-CoV-2主蛋白酶 (Mpro) 的新型COVID-19候选药物. 这项研究结合了计算建模和体外测试,以找到有效的Mpro抑制剂用于治疗开发.

科学领域:

药物的发现和开发.
计算化学是一种计算化学.
病毒学病毒学

背景情况:

由于COVID-19的流行,需要针对SARS-CoV-2的新疗法.
病毒主要蛋白酶 (Mpro) 对于病毒复制至关重要,也是关键的药物标.

研究的目的:

确定SARS-CoV-2主要蛋白酶 (Mpro) 的新型抑制剂.
开发一个强大的计算和实验工作流程,以快速发现候选药物.

主要方法:

集成的基于联体的药模拟和基于结构的虚拟选,大约有2亿种化合物.
分子动力学模拟来分析化合物-Mpro相互作用.
在体外酶分析以验证抑制活性.

主要成果:

从一个大规模的虚拟屏幕上确定了一份有希望的Mpro抑制剂候选人的名单.
两种化合物对Mpro酶表现出显著的微分子抑制活性.
验证了计算方法在预测活性抑制剂中的有效性.

结论:

这项研究为开发针对Mpro的先进COVID-19治疗方法提供了有价值的支架.
综合计算和实验方法加快了潜在候选药物的识别.

更多相关视频

Analysis of Group IV Viral SSHHPS Using In Vitro and In Silico Methods

Analysis of Group IV Viral SSHHPS Using In Vitro and In Silico Methods

Published on: December 21, 2019

Engineering Antiviral Agents via Surface Plasmon Resonance

Engineering Antiviral Agents via Surface Plasmon Resonance

Published on: June 14, 2022

相关概念视频

Coronavirus

Coronavirus

Coronaviruses, including the severe acute respiratory syndrome coronavirus (SARS-CoV), are enveloped viruses characterized by their single-stranded, positive-sense RNA genome and helical nucleocapsid structure. The hallmark of these viruses is their club-shaped spike (S) glycoproteins that protrude from the viral envelope, facilitating attachment to host cells. Typically, coronaviruses infect the upper respiratory tract, often causing mild or asymptomatic disease. However, certain strains like...